0001193125-15-315269.txt : 20150909 0001193125-15-315269.hdr.sgml : 20150909 20150909091229 ACCESSION NUMBER: 0001193125-15-315269 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20150909 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20150909 DATE AS OF CHANGE: 20150909 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ATHENAHEALTH INC CENTRAL INDEX KEY: 0001131096 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 043387530 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33689 FILM NUMBER: 151098059 BUSINESS ADDRESS: STREET 1: 311 ARSENAL STREET CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-402-1000 MAIL ADDRESS: STREET 1: 311 ARSENAL STREET CITY: WATERTOWN STATE: MA ZIP: 02472 8-K 1 d10642d8k.htm FORM 8-K Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) September 9, 2015

 

 

athenahealth, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-33689   04-3387530

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

311 Arsenal Street, Watertown, MA   02472
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: 617-402-1000

 

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 9, 2015, athenahealth, Inc. (the “Company”) announced that Robert L. Cosinuke, the Company’s current Senior Vice President and Chief Marketing Officer, will step down to assume a newly-created role with the athenahealth Leadership Institute, effective January 2016.

 

Item 7.01 Regulation FD Disclosure.

On September 9, 2015, the Company issued a press release announcing Mr. Cosinuke’s transition from Senior Vice President and Chief Marketing Officer to a newly-created role with the athenahealth Leadership Institute and additional new roles and responsibilities for certain members of its senior leadership team. A copy of the press release is attached hereto as Exhibit 99.1.

The information included in this Current Report on Form 8-K pursuant to Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit
No.

  

Description

99.1    Press release issued by athenahealth, Inc. on September 9, 2015, furnished herewith.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    

athenahealth, Inc.

     (Registrant)

September 9, 2015

    

/s/ KRISTI A. MATUS

     Kristi A. Matus
    

Executive Vice President and

Chief Financial & Administrative Officer

EX-99.1 2 d10642dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

athenahealth Announces New Executive Roles and Responsibilities

Tim O’Brien to Become Chief Marketing Officer; Rob Cosinuke to Head Leadership Institute; Dan Haley Named General Counsel; Kyle Armbrester to Hold Chief Product Officer Position

WATERTOWN, Mass., September 9, 2015 — athenahealth, Inc. (ATHN), a leading provider of cloud-based services and mobile applications for medical groups and health systems, today announced several changes within the executive team’s responsibilities to support the company’s strategic goals and growth.

Tim O’Brien will become Chief Marketing Officer, effective January 2016. In this role, he will lead all marketing and Epocrates initiatives, using his leadership experience in operations as athenahealth scales. Mr. O’Brien has held several leadership roles at athenahealth, focusing on the organization’s corporate and business development, enterprise, and corporate strategy initiatives. During the past several months he has led core marketing initiatives including channels, inside sales, and client activation. Most recently, Mr. O’Brien has managed integration efforts between Epocrates and athenahealth, a responsibility he will maintain.

After nearly eight years helping lead athenahealth’s successful growth, current Chief Marketing Officer Rob Cosinuke will step down to assume a newly-created role with the athenahealth Leadership Institute, a key initiative designed to help organizations thrive as they migrate from fee-for-service to outcomes-based care. Mr. Cosinuke will remain in his current role until the end of year, continuing to work closely with Mr. O’Brien during the transition.

Dan Haley has been named General Counsel, effective immediately, replacing Daniel Orenstein, who is leaving the company to pursue new professional opportunities. Mr. Orenstein will continue to serve the company through the end of the year as an advisor to the General Counsel, providing the benefit of his long experience and ensuring a smooth and seamless transition. For the past three years Mr. Haley has served as Vice President of Government and Regulatory Affairs and Assistant General Counsel. Before joining athenahealth, Mr. Haley was a partner at the global law firm McDermott, Will & Emery and previously served in Massachusetts state government as Deputy Legal Counsel and Deputy Chief of Staff to then-Governor Mitt Romney.


The company also announced that Kyle Armbrester will assume the role of Chief Product Officer, effective immediately. He has been the Acting Chief Product Officer since May 2015.

“We have always believed that shifting responsibilities and cultivating talent internally is important for building and maintaining an outstanding team,” said athenahealth Chief Executive Officer Jonathan Bush. “We are fortunate that our bench is deep enough to move the right people to the upper ranks. Tim, Dan, and Kyle have all proven incredibly successful in multiple roles at athenahealth and have already been serving in their new roles to some extent to make sure the transitions are smooth. I am thrilled to be keeping Rob Cosinuke’s creative talent in the company. The tradition of senior leaders staying on to mentor their chosen successors is one of which this company is particularly proud. I am excited about this realignment of responsibilities; it best positions athenahealth to successfully pursue opportunities ahead as we build the health care internet.”

About athenahealth, Inc.

athenahealth is a leading provider of cloud-based services for electronic health records (EHR), revenue cycle management and medical billing, patient engagement, care coordination, and population health management, as well as Epocrates® and other point-of-care mobile apps. We connect care® and drive meaningful, measurable results for more than 67,000 healthcare providers in medical practices and health systems nationwide. For more information, please visit www.athenahealth.com.

Forward-Looking Statements

This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the realignment of executive roles and responsibilities, timing of the changes and the positioning of athenahealth to pursue future opportunities to build the health care internet. These statements are neither promises nor guarantees, and are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. athenahealth undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances, or otherwise. For additional disclosure regarding these and other risks faced by athenahealth, please see the disclosure contained in our public filings with the Securities and Exchange Commission (SEC), available on the Investors section of our website at http://www.athenahealth.com and on the SEC’s website at http://www.sec.gov.


Contact:

Holly Spring

athenahealth, Inc. (Media)

media@athenahealth.com

617-402-1631

Dana Quattrochi

athenahealth, Inc. (Investors)

investorrelations@athenahealth.com

617-402-1329

GRAPHIC 3 g10642001.jpg GRAPHIC begin 644 g10642001.jpg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end